SCHEMBL55948

SCHEMBL55948

CC(C)(N)C1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
RIPK1 Q13546 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL55994 0.97 ALDH1A1 (0.44) ALDH1A1TDP1
SCHEMBL1231253 0.78 ALDH1A1 (0.57) ALDH1A1TDP1
SCHEMBL1679082 0.78
SCHEMBL179281 0.77 CYP1A2 (0.40)
SCHEMBL16689109 0.77 PIK3CD (0.30)
Hydrochloric Acid SCHEMBL8999629 0.76
SCHEMBL9289736 0.75 PIK3CD (0.32)
SCHEMBL3141477 0.73
SCHEMBL3145557 0.73
SCHEMBL24310239 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117396480-A Pyrazolopyrimidinone compounds 奥弗恩制药公司 2024-01-12 CN disclosed
WO-2022204481-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS Orphagen Pharmaceuticals, Inc. (US) 2022-09-29 WO disclosed
US-20220153711-A1 P14-Kinase Inhibitors and Methods of Using the Same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2022-05-19 US disclosed
US-20220017507-A1 PI-Kinase Inhibitors with Anti-Infective Activity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-01-20 US disclosed
US-11091472-B2 PI-kinase inhibitors with anti-infective activity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-08-17 US disclosed
WO-2020191205-A1 PI4-KINASE INHIBITORS AND METHODS OF USING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-09-24 WO disclosed
WO-2017147526-A1 PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2017-08-31 WO disclosed
EP-2420491-B1 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2013-07-03 EP disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
WO-2011013644-A1 SUBSTITUTED PIPERIDINE COMPOUND 第一三共株式会社 (JP) 2011-02-03 WO disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
EP-1968940-A1 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS Novartis AG (CH) 2008-09-17 EP disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 ALDH1A1 38/4885TDP1 2580/4885RIPK1 4263/4885
US-11091472-B2 PI-kinase inhibitors with anti-infective activity PIP4K2A, PIP5K1A, PIP4K2C ALDH1A1 4825/4885TDP1 2835/4885RIPK1 139/4885
US-20220153711-A1 P14-Kinase Inhibitors and Methods of Using the Same PI4KB, PI4KA, PI4K2A ALDH1A1 4682/4885TDP1 1975/4885RIPK1 298/4885
US-20220017507-A1 PI-Kinase Inhibitors with Anti-Infective Activity PIP4K2A, PIP5K1A, PIP4K2C ALDH1A1 4818/4885TDP1 2833/4885RIPK1 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.